Sun Pharmaceutical Industries Ltd. — Capital/Financing Update 2021

Mar 31, 2021

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com CIN: L24230GJ1993PLC019050

Sun House, Plot No. 201 B/1,

Sun Pharmaceutical Industries Limited

Date: 31.03.2021

To, National Stock Exchange of India Ltd, BSE Ltd., Exchange Plaza, 5th Floor, Market Operations Dept. Plot No. C/1, G Block, P. J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 051. Mumbai - 400 001.

Scrip Name: SUNPHARMA Scrip Code: 524715

Dear Sir/ Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015.

We would like to inform you that our wholly owned Indian subsidiary's investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) has through its wholly-owned entity DigiHealth Technologies LLP, acquired 66.02% ownership interest in AIOCD Pharmasofttech Awacs Private Limited ("AWACS") though a combination of (i) direct purchase of 50% ownership interest in AWACS and (ii) indirect purchase of 16.02% ownership interest in AWACS through acquisition of 32.04% shareholding interest in Trikaal Mediinfotech Private Limited. It is also agreed to acquire the balance stake subject to fulfilment of certain terms and conditions.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September, 2015 are given in Annexure 1 to this letter.

We request you to kindly take this in your record and disseminate.

Thanking you,

Yours Sincerely For Sun Pharmaceutical Industries Limited

Ashok Indulal Bhuta Digitally signed by Ashok Indulal Bhuta Date: 2021.03.31 20:17:46 +05'30'

[Ashok Bhuta] Compliance Officer

Encl: As above

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com CIN: L24230GJ1993PLC019050

ANNEXURE – 1

Details as per the Securities and Exchange Board of India circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015

Sr. No.	Particulars	Detail
a.	Name of the target entity, details in briefsuch as size, turnover etc.	(i)Name of the Target Entities:AIOCDPharmasofttechAwacsPrivateLimited("AWACS").TrikaalMediinfortechPrivateLimited("Trikaal")(ii)Details of the Target Entities:AWACS is engaged in the business ofpharmaceutical data collection and marketresearch.Trikaal is 50% owner of AWACS and holdscertain intellectual property in relation toAWACS's business.
b.	Whether the acquisition would fall withinrelated party transaction(s)and whetherthepromoter/promotergroup/groupcompanies have any interest in the entitybeing acquired? If yes, nature of interestand details thereof and whether the sameis one at "arms length"	Not a related party transaction.
c.	Industry to which the entity beingacquired belongs	Healthcare Services
d.	Objectsandeffectsofacquisition(including but not limited to, disclosure ofreasons for acquisition of target entity, ifits business is outside the main line' ofbusiness of the listed entity)	A step by ABCD Technologies LLP (to berenamedasIndoHealthServicesLLP)towards the initiative with an objective tofacilitate, enable and promote efficiency andGoodDistributionPractices('GDP')including digitizing healthcare infrastructurein India, inter alia, in support of the NationalDigital Health Mission of Government ofIndia ('Business').The acquisition is and willbedonebyitswhollyownedentityDigiHealth Technologies LLP.

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com CIN: L24230GJ1993PLC019050

e.	Brief details of any governmental orregulatory approvals required for theacquisition	Not Applicable
f.	Indicative time period for completion ofthe acquisition	The acquisition of 66.02% of shareholding inAWACS (direct and indirect together) hasbeen completed on 30th of March, 2021.Theacquisitionof33.44%oftheshareholdinginAWACS(indirect)isenvisaged to be completed over the course ofnext few months subject to fulfilment ofcertain terms and conditions.The remaining 0.54% of the shareholding inAWACS (indirect) islikely to be acquiredafter 05 years (FY: 2026-'27)
g.	Nature of consideration -whether cashconsideration or share swap and detailsof the same	Cash Consideration payable by DigiHealthTechnologies LLP
h.	Cost of acquisition or the price at whichthe shares are acquired	The cost of acquisition for the combinedtransactionofAWACSandTrikaalisapproximately INR 75 crores for acquisitionof 100% stake in AWACS and Trikaal (directand indirect together).
i.	Percentage of shareholding /control acquired and / or numberof shares acquired	Please refer to the response provided in pointf above.
j.	Briefbackgroundabouttheentityacquired in terms of products/line ofbusiness acquired, date of incorporation,history of last 3 years turnover, country inwhich the acquired entity has presenceand any other significant information (inbrief)	(i)About the entities:AWACS is engaged in the business ofpharmaceutical data collection and marketresearch.Trikaalis 50% owner of AWACS and holdscertain intellectual property in relation toAWACS's business.(ii)Date of Incorporation:AWACS: September 21, 2007Trikaal: January 03, 2007

Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA. Tel. : (91-22) 4324 4324 Fax : (91-22) 4324 4343 Website: www.sunpharma.com CIN: L24230GJ1993PLC019050

	(iii)Turnover historyof last 3 years:
	AWACS:
	2019-2020: 15,31,95,1032018-2019:16,15,30,6972017-2018: 16,30,86,020
	Trikaal:
	2019-2020: Nil2018-2019: Nil2017-2018: 1,10,00,000
	(iv)Country: India